Dosing the antipsychotic medication olanzapine

Charles B. Nemeroff

Research output: Contribution to journalArticlepeer-review

159 Scopus citations


Olanzapine is a new antipsychotic agent with serotonin/dopamine antagonism action. Efficacy in treating overall psychopathology in acute schizophrenia as measured by the BPRS0-6 total score was demonstrated at 10 mg/day versus placebo; at doses in a 5-20 mg/day range, olanzapine was comparable or superior to haloperidol. Superior efficacy for negative and depressive symptoms was shown in comparison to haloperidol. Olanzapine has a favorable acute and tardive extrapyramidal symptom profile relative to haloperidol and caused substantially less elevation of serum prolactin. Dose- related weight gain and asymptomatic mild transaminase elevations occurred in olanzapine-treated patients.

Original languageEnglish (US)
Pages (from-to)45-49
Number of pages5
JournalJournal of Clinical Psychiatry
Issue numberSUPPL. 10
StatePublished - Aug 20 1997
Externally publishedYes

ASJC Scopus subject areas

  • Psychiatry and Mental health


Dive into the research topics of 'Dosing the antipsychotic medication olanzapine'. Together they form a unique fingerprint.

Cite this